Prostate regrowth was monitored at day zero, three, seven, and 28 days following implantation of exogenous testosterone.
Immune responses were monitored at day 6 after vaccination with each vector to assess the levels of activated T cells and neutralizing antibody detectable just before mice are expected to succumb to a mouse-adapted Ebola challenge of 1000×LD50 (between 7 to 10 days post-challenge).
Importantly, IVIg-mobilized CD19+CD27high cell counts strongly correlated with plasma cell counts measured by blood smears (r = 0.94, p<0.0001, n = 67, data not shown), indicating that the same type of plasma cell was indeed monitored at day 7 of IVIg in both retrospective and prospective studies.
Of 713 patients, 560 (cohort A), 190 (cohort B), and 172 (cohort C) had serum creatinine monitored at 3 days, 30 days, and 6 months after angiography, respectively.
Therefore, in the following experiments, primary CTL responses were monitored at 7 days after immunization.
The course of the infection was monitored at various days post challenge by in vivo imaging.
Animals received three doses of pmir122 injection, and the parasite load was monitored at 30 days p.i.
The groups were then returned to standard rodent diet with/without supplementation with compounds 4 or 8. Body weight and food intake was monitored at 3 4 day intervals.
Active and total ghrelin, growth hormone (GH), and insulin-like growth factor 1 levels were monitored at baseline (4 5 days before day 1), during treatment days, and at end of study (day 17/18).
